Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study
Authors:
- Mariano Ponz-SarviséMPMariano Ponz-Sarvisé
- Sun Young. RhaSRSun Young. Rha
- Carlos A. Gomez-RocaCGCarlos A. Gomez-Roca
- Laura Ortega MoránLMLaura Ortega Morán
- Sanjeev GillSGSanjeev Gill
- Giampaolo TortoraGTGiampaolo Tortora
- Ravit GevaRGRavit Geva
- Esma Saada-BouzidESEsma Saada-Bouzid
- Armando SantoroASArmando Santoro
- Tae Won. KimTKTae Won. Kim
- Daniel HeudoblerDHDaniel Heudobler
- Corina E. DutcusCDCorina E. Dutcus
Top Cited Papers
Open Access
- 1 March 2026
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 6 (3) , 673-686
Abstract
Purpose: Patients with gastric cancer, biliary tract cancer (BTC), and pancreatic ductal adenocarcinoma (PDAC) have poor survival outcomes and limited second- or later-line treatment options. Certain drugs targeting vascular endothelial growth factor (VEGF) or programmed cell death protein 1 (PD-1) signaling pathways are currently used in these cancers in specific circumstances; however, there remains a need for novel treatment combinations. LEAP-005 is a multicohort, open-label, phase II study that evaluated lenvatinib (multitargeted inhibitor of tyrosine kinases, including VEGF) plus pembrolizumab (anti–PD-1 monoclonal antibody) in select previously treated solid tumors. Patients and Methods: Participants with previously treated, advanced gastric cancer, BTC, and PDAC were enrolled in cohorts C, F, and G of LEAP-005, respectively, and received lenvatinib 20 mg/day orally plus pembrolizumab 200 mg i.v. every 3 weeks. Primary endpoints were objective response rate (ORR) and safety. Results: Of 99, 102, and 103 total participants enrolled in cohorts C, F, and G, respectively, median times from first dose of study treatment to data cutoff (February 6, 2023) were 23.7, 24.2, and 19.5 months. ORRs (95% confidence interval) by blinded independent central review were 15.2% (8.7%–23.8%) in cohort C, 17.6% (10.8%–26.4%) in cohort F, and 7.8% (3.4%–14.7%) in cohort G. Grade 3 to 5 treatment-related adverse events occurred in 54.5% of participants in cohort C, and grade 3 to 4 (no grade 5) occurred in 60.8% and 59.2% of participants in cohorts F and G, respectively. Conclusions: Lenvatinib plus pembrolizumab demonstrated modest antitumor activity and a manageable safety profile in previously treated, advanced gastric cancer, BTC, and PDAC. Significance: In the phase II LEAP-005 study, lenvatinib plus pembrolizumab showed modest antitumor activity and a manageable safety profile in participants with previously treated gastrointestinal-related cancers. Exploratory analyses in participants with BTC indicated higher ORRs in participants with targetable alterations versus those without.Keywords
All Related Versions
Funding Information
- MSD Sharp and Dohme
This publication has 61 references indexed in Scilit:
- 44P Chemo-immunotherapy combination of mFOLFOX6, bevacizumab and atezolizumab after first-line therapy for advanced biliary tract cancer: The COMBATBIL imCORE trialAnnals of Oncology, 2024
- Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumabGastric Cancer, 2021
- LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumoursAnnals of Oncology, 2020
- Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studiesInternational Journal of Cancer, 2020
- A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update dataGastric Cancer, 2019
- Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal AdenocarcinomaJAMA Oncology, 2019
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction CancerJAMA Oncology, 2018
- Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinomaInvestigational New Drugs, 2017
- A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapyCancer Chemotherapy and Pharmacology, 2012
- Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)European Journal of Cancer, 2011